News & Media

IMRIS Inc. announced the sale of IMRISneuro to the University Hospital Tübingen, located in Tübingen, Germany.

DiaMedica announced antihypertensive results with its lead monoclonal antibody DM-204. Consistent and significant blood pressure lowering results are observed with DM-204 in all animals and the lower blood pressure occurred for the duration of the study

Science Applications International Corporation (SAIC) announced it was awarded a contract extension by the National Aeronautics and Space Administration (NASA) for the Unified NASA Information Technology Services (UNITeS) contract

Valeant Pharmaceuticals International, Inc. announces fourth quarter financial results for 2010.

Kane Biotech has been named one of the top ten companies in the biotech industry by Fast Company in its annual list of the world’s “Most Innovative Companies.

The governments of Canada and Manitoba announced $2.6 million for the expansion of the Food Development Centre (FDC). Manitoba Agriculture, Food and Rural Initiatives (MAFRI) Minister Stan Struthers and Federal Member of Parliament Candice Hoeppner (Porta

The Manitoba government will assist the Pan Am Clinic in working with Echometrix LLC to assess the use of innovative ultrasound technology to diagnose and treat soft-tissue injuries and conditions, Innovation, Energy and Mines Minister Dave Chomiak announ

Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has signed a letter of intent (LOI) with PreMD Inc. to license the exclusive world

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce that the Company’s Research and Development (R&D) team has made contributions to two new scie

Medical technology company IMRIS Inc. (TSX:IM) booked its first-ever positive results as revenues more than tripled in the fourth quarter.

Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, today announces a non-brokered private placement offering (the “Offering”) of up to 7,150,000 units (“Units”) at

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 2003284385 entitled “Compositions and methods for enzymatic detac

GVI Clinical Development Solutions (GVI-CDS), an innovative CRO focused on quality, timeliness and cost effective services, is pleased to announce that Douglas A. Elliott and Sandra Reis have joined GVI-CDS.

Agreement Includes Fee From Inverness to Acquire Exclusive Option to License Worldwide Rights.

DiaMedica Inc. (TSX-V:DMA) (“Diamedica”), a biopharmaceutical company that has discovered and is developing a novel approach to treating diabetes, announces it has entered into a non-binding letter of intent to acquire all of the issued and outstanding sh

Drug firm concentrates all its work in Manitoba

Winnipeg and the Province of Manitoba will benefit from an initiative to increase local economic activity, thanks to $280,000 in support from the Governments of Canada and Manitoba.

Cangene Corporation today reports financial results for the fiscal year ended July 31, 2009.

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce that the Company has been selected to present at the Partners in Biomedical Defence 2009 Conf

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that BioVectra has successfully completed the manufacturing of DispersinB® Topical Wound Gel un

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce the issuance of Patent No. 7,556,807 entitled “Signal peptides, nucleic acid molecules and me